Aethlon Medical Stock (NASDAQ:AEMD), Trade Ideas

Aethlon Medical

Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

AMZN

BGLC

BRSH

BZFD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CUEN

FFIE

HSCS

IKNA

IMPL

IRBT

IVDA

RELI

SEEL

TBIO

VBIV

WLGS

Shares of  Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) surged in pre-market trading after the company announced its foray into the Middle Ea

Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Intraday Update

ACHR

AFRM

ALLR

ALXO

APLD

ASLN

BNED

Borqs Technologies, Inc. - Ordinary Shares

BRQS

BURU

CALT

CRBU

CYBN

FRGT

GENI

HLLY

IMBI

MCOM

MINM

MULN

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

NYMX

OPAD

PERI

PLCE

TTCF

TTOO

UGRO

UPST

XXII

Gainers


	Caribou Biosciences, Inc.  (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer.


Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday&#39;s Session

ADTX

ALPP

ASTI

AUGX

BBBY

CFRX

CNSP

EGBN

FFIV

GETR

GETY

GSUN

LSDI

MATX

MDXH

MIND

MNKD

NBSE

NOVA

NVAX

NVRO

OMER

PHGE

PTPI

SatixFy Communications Ltd. Ordinary Share

SATX

SKLZ

SNAP

TNYA

TSLA

UFAB

UIHC

VCIG

WINT

ZION

Gainers


	Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase agreement to acquire 50% ownership of Global Response Aid with rights to manufacture and market broad-spectrum antiviral drug Avigan.


Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Aethlon Medical Inc

<a href="https://twitter.com/DrTedros/status/1778423967105139108">https://twitter.com/DrTedros/status/1778423967105139108</a>
&nbsp;
&nbsp;

Biotech

Global

General

CMRX

GOVX

MRNA

SIGA

TNXP

WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."

HC Wainwright &amp; Co. analyst Vernon Bernardino maintains Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Buy and lowers the price target from $23 to $10.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Aethlon Medical, Lowers Price Target to $10

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier&#xAE; Blood Filtration System
SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4095896-1&amp;h=2596990404&amp;u=https%3A%2F%2Fwww.aethlonmedical.com%2F&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.
Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
Aethlon will perform initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture devices, alone, and in combination with Aethlon's Hemopurifier&#xAE; -- a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids -- to assess their ability to remove important targets in samples from cancer patients, as well as from perfusates from kidneys that have undergone machine perfusion as part of the renal transplantation process.
"We look forward to initiating pre-clinical studies shortly, to expand upon the data that Santersus has generated in sepsis and liver and lung transplantation, and more importantly, to explore potential synergies with our Hemopurifier, initially in oncology and renal transplantation, as well as other potential indications," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Our belief is that the NETs removed by the NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators removed by our Hemopurifier, could have an additive or synergistic effect in both the cancer and kidney transplant settings. The signing of the MTA represents an important milestone for both companies, as it is the first step toward a potential future collaboration."
"Our collaboration with Aethlon has provided us with research and development partners with expertise and capabilities to help &nbsp;advance our NucleoCapture technology platform forward in important fields, such as oncology and kidney transplantation. We are excited to continue building on the progress we've made in Santersus thus far and on taking the next steps forward in executing on our plans to advance NucleoCapture technology," commented Scott Maguire, Chairman of Santersus. &nbsp;"NETs are being increasingly recognized as an important element in cancer progression and metastasis. We believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with Hemopurifier technology might create a transformational treatment option for patients receiving immune checkpoint inhibitors or CAR T cell therapies."

Aethlon Medical Enters Into Materials Transfer Agreement For Santersus AG's NucleoCapture And HemoNucleoCapture Devices

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported its Q3 earnings results on Wednesday, February 14, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Aethlon Medical missed estimated earnings by 11.38%, reporting an EPS of $-1.37 versus an estimate of $-1.23.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.18 which was followed by a 7.55% increase in the share price the next day.

To track all earnings releases for Aethlon Medical <a href="https://www.benzinga.com/quote/AEMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Aethlon Medical Q3 Earnings

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.23) by 11.38 percent. This is a 14.17 percent decrease over losses of $(1.20) per share from the same period last year.

Earnings Misses

Aethlon Medical Q3 EPS $(1.37) Misses $(1.23) Estimate

ACGL

ADPT

AMWL

ATEX

ATMU

ATUS

AVNT

AVTR

AYTU

BLIN

BXMT

BYRN

CCRD

CEVA

CHEF

CNDT

CNHI

CNVS

CNXN

CRWS

CSCO

CSPI

EPRT

EQIX

FBRT

FCPT

FROG

FSLY

GLDD

GNRC

GOLD

GPMT

HCSG

HUBS

INFA

ISSC

KRNT

MCRI

MITQ

MMLP

NATL

NMIH

NRDS

NTST

PEGA

PGRE

PLMR

POCI

PTEN

PYPD

QIPT

RBBN

Earnings Scheduled For February 14, 2024

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Here's what investors need to know before the announcement.
Analysts estimate that Aethlon Medical will report an earnings per share (EPS) of $-1.23. 
Aethlon Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.18, which was followed by a 7.55% increase in the share price the next day.
Here's a look at Aethlon Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.40</td>
<td>-1.3</td>
<td></td>
<td>-0.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.22</td>
<td>-1.4</td>
<td>-1.1</td>
<td>-1.2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.55%</td>
<td>-0.81%</td>
<td>-5.07%</td>
<td>-3.59%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Aethlon Medical were trading at $1.75 as of February 12. Over the last 52-week period, shares are down 67.61%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AEMD/earnings">To track all earnings releases for Aethlon Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Aethlon Medical

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 19.8% to $0.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 17.61% to $0.37. The company's market cap stands at $11.1 million. </li>
<li>scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) stock increased by 16.47% to $6.22. The company's market cap stands at $223.0 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 16.32% to $0.29. The company's market cap stands at $2.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares rose 15.95% to $5.67. The company's market cap stands at $34.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 20.9% to $1.5 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) shares fell 20.44% to $3.7. The company's market cap stands at $112.6 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares declined by 17.86% to $5.75. The market value of their outstanding shares is at $6.0 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 13.3% to $0.91. The company's market cap stands at $7.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 11.17% to $0.37. The market value of their outstanding shares is at $16.5 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares decreased by 9.7% to $0.27. The company's market cap stands at $57.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRG

BNOX

CELU

LIFW

NEXI

OPGN

SCPH

SNTI

SXTP

XBIT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter">https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter</a>
The World Health Organization is "very worried" about the spread of a severe form of mpox that has killed nearly 600 people, mainly children, in the Democratic Republic of Congo this year, a senior official said.
The country has reported over 13,000 cases in 2023, more than twice as many as during the last peak in 2020, with the disease occurring in almost every province. The WHO is working with the authorities on the response and a risk assessment.
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) <a href="https://www.reuters.com/world/africa/us-cdc-issues-health-alert-subtype-mpox-virus-congo-2023-12-07/">issued an alert</a> about the dangerous clade I mpox outbreak.
"The virus variant is known to be more virulent. If it adapts better to human to human transmission, that presents a risk," Rosamund Lewis, WHO's mpox lead, told Reuters by phone from Kinshasa.
Mpox is a viral infection that spreads through close contact, causing flu-like symptoms and pus-filled lesions. Most cases are mild but it can kill.
Last year, a less severe form – clade II – began to spread globally, largely through sexual contact among men who have sex with men, and the WHO declared a public health emergency.
New evidence that clade I can also spread through sexual contact is concerning, Lewis said. Mpox can also spread to humans from infected animals or among family members within households, she said. Children and people with weak immune systems are more at risk, with illness leading to death in up to 10% of clade I cases.
"We have very little information of who is dying of mpox [in DRC] other than age," said Lewis, adding more data was needed.
The WHO is also worried about an outbreak among sex workers in South Kivu, because of the vulnerability of the population as well as the risk of the infection spreading to neighbouring countries, she said.
The agency is working with the Congo government to resolve <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/stigma-regulatory-barriers-delay-mpox-response-country-that-needs-it-most-2023-12-05/">regulatory</a> hurdles to enable the country to procure or accept donations of mpox vaccines, currently only available in the country in ongoing clinical studies. There is also a mpox antiviral treatment trial underway.
DRC has not requested any treatments, Lewis said. Getting the vaccine is more complex, she added, because only one region of the WHO has a supply agreement in place. Any donations would also need funding for deployment.

Reported Earlier, "WHO 'Very Worried' About Spread Of Mpox In DRC" - Reuters News

<h3>Gainers</h3>
<ul>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 32.5% to $0.53 during Friday's pre-market session. The company's market cap stands at $15.8 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) shares increased by 14.9% to $1.05. The company's market cap stands at $22.7 million. </li>
<li>Medigus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGS#NASDAQ">MDGS</a>) stock rose 10.99% to $3.13. The company's market cap stands at $5.3 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 10.0% to $0.55. The company's market cap stands at $5.1 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock moved upwards by 9.99% to $0.71. The company's market cap stands at $46.7 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares moved upwards by 9.8% to $1.12. The market value of their outstanding shares is at $1.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares declined by 96.8% to $0.35 during Friday's pre-market session. </li>
<li>Impel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>) stock declined by 31.96% to $0.53. The company's market cap stands at $12.6 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares decreased by 17.16% to $1.4. The company's market cap stands at $3.4 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares declined by 12.27% to $1.43. The company's market cap stands at $69.0 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) shares fell 10.74% to $0.7. The market value of their outstanding shares is at $6.8 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock decreased by 10.56% to $0.21. The market value of their outstanding shares is at $10.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.